Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.88 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.88 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | PDE6D | O43924 | 1/20 | 0.53 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25473202 | 1.00 | CRBN (0.88) | CRBNDDB1STAT3PDE6DGSPT1 | |
| SCHEMBL20208237 | 1.00 | CRBN (0.88) | CRBNDDB1STAT3PDE6DGSPT1 | |
| SCHEMBL26837670 | 1.00 | CRBN (0.88) | CRBNDDB1STAT3PDE6DGSPT1 | |
| SCHEMBL20208349 | 1.00 | CRBN (0.88) | CRBNDDB1STAT3PDE6DGSPT1 | |
| SCHEMBL24046261 | 1.00 | CRBN (0.88) | CRBNDDB1STAT3PDE6DGSPT1 | |
| SCHEMBL23057485 | 0.99 | CRBN (0.90) | CRBNDDB1STAT3PDE6DGSPT1 | |
| SCHEMBL20208371 | 0.99 | CRBN (0.90) | CRBNDDB1STAT3PDE6DGSPT1 | |
| SCHEMBL22276517 | 0.96 | CRBN (0.84) | CRBNDDB1STAT3PDE6DGSPT1 | |
| SCHEMBL20153910 | 0.94 | CRBN (1.00) | CRBNDDB1STAT3GSPT1 | |
| SCHEMBL20208207 | 0.91 | DDB1 (0.87) | CRBNDDB1STAT3GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240263184-A1 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | PIONEERING MEDICINES 08- B, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-3544957-B1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11873496-B2 | Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873496-B2 | Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2024-01-16 | — | — | US | disclosed |
| EP-4249501-A2 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | Whitehead Institute for Biomedical Research (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230131952-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230131952-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| EP-3565891-B1 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | WHITEHEAD INST BIOMEDICAL RES (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022109396-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109396-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| US-11285218-B2 | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210061811-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-20190352648-A1 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | PIONEERING MEDICINES 08- B, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20190263823-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-15 | — | — | US | disclosed |
| WO-2018129544-A1 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018098280-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130368-A1 | HETEROBIFUNCTIONAL COMPOUNDS WITH IMPROVED SPECIFICITY | MDM2, STUB1, UBE3C | CRBN 113/4885DDB1 249/4885STAT3 2082/4885 |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885STAT3 3381/4885 |
| US-20190247509-A1 | DEGRADATION OF BROMODOMAIN-CONTAINING PROTEIN 9 (BRD9) BY CONJUGATION OF BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BRD9, BRWD1, BRD1 | CRBN 186/4885DDB1 442/4885STAT3 2161/4885 |
| US-20190263823-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | MDM2, MAP2K2, TTK | CRBN 663/4885DDB1 755/4885STAT3 896/4885 |
| US-20240263184-A1 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | CTCF, JUN, ELF3 | CRBN 805/4885DDB1 180/4885STAT3 13/4885 |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CRBN 179/4885DDB1 987/4885STAT3 3892/4885 |
| US-20230131952-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | MDM2, MAP2K2, TTK | CRBN 663/4885DDB1 755/4885STAT3 896/4885 |
| US-11873496-B2 | Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops | CTCF, JUN, ELF3 | CRBN 805/4885DDB1 180/4885STAT3 13/4885 |
| US-20210061811-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | MDM2, MAP2K2, TTK | CRBN 663/4885DDB1 755/4885STAT3 896/4885 |
| US-20190352648-A1 | METHODS OF ALTERING GENE EXPRESSION BY PERTURBING TRANSCRIPTION FACTOR MULTIMERS THAT STRUCTURE REGULATORY LOOPS | CTCF, JUN, ELF3 | CRBN 805/4885DDB1 180/4885STAT3 13/4885 |
| US-11285218-B2 | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | BRD9, BRWD1, BRD1 | CRBN 186/4885DDB1 442/4885STAT3 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.